Global Anti-cd20 Monoclonal Antibodies (mabs) Market 2025-2029

Anti-CD20 Monoclonal Antibodies (MABs) Market 2025-2029

The anti-CD20 monoclonal antibodies (MABs) market is forecasted to grow by USD 15643.1 million during 2024-2029, accelerating at a CAGR of 12.3% during the forecast period. The report on the anti-CD20 monoclonal antibodies (MABs) market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increased use of combination therapies, high target affinity and specificity of anti-CD20 MABs, and strong pipeline and recent approvals.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's anti-CD20 monoclonal antibodies (MABs) market is segmented as below:

By Product

• Oncology
• Neurology
• Immunology

By Type

• First generation
• Second generation
• Third generation

By End-user

• Hospitals and clinics
• Academic and research institutions
• Contract research organizations

By Drug Class

• Rituximab
• Ofatumumab
• Obinutuzumab
• Ublituximab
• Others

By Route Of Administration

• Intravenous
• Subcutaneous

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the increasing awareness about therapeutic areas as one of the prime reasons driving the anti-CD20 monoclonal antibodies (MABs) market growth during the next few years. Also, presence of reimbursement and patient assistance programs and the development of CD20 bispecific antibodies will lead to sizable demand in the market.

The report on the anti-CD20 monoclonal antibodies (MABs) market covers the following areas:

• Anti-CD20 Monoclonal Antibodies (MABs) Market sizing
• Anti-CD20 Monoclonal Antibodies (MABs) Market forecast
• Anti-CD20 Monoclonal Antibodies (MABs) Market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading anti-cd20 monoclonal antibodies (MABs) market vendors that include Acrotech Biopharma Inc., Amgen Inc., AstraZeneca PLC, Celltrion Healthcare Co. Ltd., F. Hoffmann La Roche Ltd., Fosun International Ltd., Genmab AS, IGM Biosciences Inc., JSC BIOCAD, LFB SA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Spectrum Pharmaceuticals Inc., TG Therapeutics Inc., United BioPharma Inc., and ZHEJIANG HISUN PHARMACEUTICAL Co. Ltd.. Also, the anti-CD20 monoclonal antibodies (MABs) market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth. Show more